What type of study is this?

September 10, 2025

Increasing rates of ESBL-producing Escherichia coli and Klebsiella pneumoniae in Canadian Hospitals: 17 years of the CANWARD study, 2007–23

Key Points

Prevalence of ESBL-producing E. coli increased from 3.6% in 2007–08 to 11.8% in 2021–23, indicating a troubling trend in antibiotic resistance.
Among the isolates, 8.4% of E. coli and 5.6% of K. pneumoniae were ESBL producers, as identified in 11,931 E. coli and 3,973 K. pneumoniae samples.
Analysis of resistance patterns utilized multifactorial regression and trend analysis, emphasizing the need for continuous monitoring.
MDR E. coli decreased over time, yet high resistance to key antibiotics persists, highlighting ongoing challenges in treatment options.

Abstract

Abstract Objectives ESBL-producing Escherichia coli and Klebsiella pneumoniae are major causes of infections, including urinary tract, abdominal, nosocomial pneumonia, diabetic foot and bloodstream infections. This study examines trends in their prevalence, genotypes and antibiotic susceptibility and identifies at-risk populations. Methods Between 2007 and 2023, bacterial isolates were collected from sentinel laboratories (CANWARD study). Identification, antimicrobial susceptibility testing and WGS were performed. Trends in incidence, resistance patterns, beta-lactamase genotypes and demographic associations were analysed using multifactorial regression and trend analysis. Results Among 11 931 E. coli and 3973 K. pneumoniae isolates, 8.4% and 5.6%, respectively, were ESBL-producers, with prevalence increasing from 2007–08 to 2021–23 (E. coli: 3.6% to 11.8%; K. pneumoniae: 2.2% to 8.0%; P 0.001). Susceptibility among ESBL E. coli declined for amoxicillin-clavulanate (78.7% to 28.6%) but increased for gentamicin (43.5% to 70.3%) (P 0.001). MDR among ESBL-positive E. coli declined (82.4% to 63.4%; P 0.001) but remained stable among ESBL-positive K. pneumoniae. ESBL E. coli was associated with inpatients, respiratory specimens and males, while K. pneumoniae was linked to inpatient status and regional variations. Genotypic analysis showed increasing blaCTX-M-15 in K. pneumoniae and blaCTX-M-27 in E. coli. blaOXA-1 and blaTEM-1 were associated with MDR and first-generation β-lactam/β-lactamase inhibitor resistance. Conclusion ESBL E. coli and K. pneumoniae have increased in prevalence, with evolving resistance patterns. While MDR in E. coli has declined, resistance to key antimicrobials, including sulphonamides, fluoroquinolones and first-generation β-lactam/β-lactamase inhibitors remains high. Resistance rates varied significantly by region of Canada and by inpatient status, sex and specimen type.

AI에게 질문

Bookmark

Cite This Study

Lagacé‐Wiens et al. (Sat,) studied this question.

synapsesocial.com/papers/68c1dda254b1d3bfb60fc6c7 https://doi.org/https://doi.org/10.1093/jac/dkaf220

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

AI에게 질문

Bookmark